- Record: found
- Abstract: not found
- Article: not found
A Phase I/Ii Study of Evofosfamide, A Hypoxia-Activated Prodrug With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
JP Laubach, CJ Liu, NS Raje, AJ Yee, P Armand, RL Schlossman, S. KATO, A. GOODMAN, V Walavalkar, D.A. Barkauskas, A SHARABI, R Kurzrock, U. Kortmann, J.N. McAlpine, H Xue, K. Berns, A Sonnenblick, A. Gennissen, S. Broheé, E. Hijmans, B Evers, D Fumagalli, C Desmedt, S Loibl, C Denkert, P Neven, W Guo, F Zhang, T. Knijnenburg, T Bosse, M. VAN DER HEIJDEN, S Hindriksen, W. Nijkamp, Lodewyk Wessels, H Joensuu, G. Mills, Roderick L Beijersbergen, C Sotiriou, R Bernards, F. ZHANG, LODEWYK F. A. WESSELS, H. JOENSUU, T Goldstein, E.O. Paull, M.J. Ellis, J. Stuart, F Bouquet, A Pal J, KA Pilones, S. DeMaria, B Hann, RJ Akhurst
2019
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.